SCHEMBL1161573

SCHEMBL1161573

NC(=O)CCS(=O)(=O)c1ccccc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 4/20 0.65
L3MBTL1 Q9Y468 1/20 0.59
CA12 O43570 1/20 0.54
CA1 P00915 1/20 0.54
CA2 P00918 1/20 0.54
CA9 Q16790 1/20 0.54
KDM4E B2RXH2 1/20 0.52
MAPT P10636 1/20 0.51
HDAC3 O15379 1/20 0.51
HDAC4 P56524 1/20 0.51
HDAC1 Q13547 1/20 0.51
HDAC7 Q8WUI4 1/20 0.51
HDAC2 Q92769 1/20 0.51
HDAC10 Q969S8 1/20 0.51
HDAC11 Q96DB2 1/20 0.51
HDAC8 Q9BY41 1/20 0.51
HDAC6 Q9UBN7 1/20 0.51
HDAC9 Q9UKV0 1/20 0.51
HDAC5 Q9UQL6 1/20 0.51
RAB9A P51151 4/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2810870 0.90 HDAC1 (0.58) HSD11B1L3MBTL1CA12CA1CA2
SCHEMBL27466099 0.89 MMP2 (0.59) HSD11B1L3MBTL1CA12CA1CA2
Hydrochloric Acid SCHEMBL5124026 0.89 HDAC1 (0.57) HSD11B1L3MBTL1CA12CA1CA2
SCHEMBL7771540 0.89 HDAC1 (0.66) HSD11B1L3MBTL1CA12CA1CA2
SCHEMBL11466743 0.87 HDAC1 (0.69) HSD11B1L3MBTL1CA12CA1CA2
SCHEMBL2807341 0.87 HDAC1 (0.69) HSD11B1L3MBTL1CA12CA1CA2
SCHEMBL7773680 0.87 HDAC1 (0.69) HSD11B1L3MBTL1CA12CA1CA2
SCHEMBL8189068 0.85 MMP1 (0.69) HSD11B1POLBSMN1; SMN2HTTKMT2A
SCHEMBL1001018 0.83 HSD11B1 (0.69) HSD11B1L3MBTL1CA12CA1CA2
SCHEMBL5466697 0.82 HSD11B1 (0.58) HSD11B1L3MBTL1CA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2461683-A1 BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS Biogen Idec MA Inc. (US) 2012-06-13 EP claimed
WO-2011017561-A1 BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS BIOGEN IDEC MA INC. (US) 2011-02-10 WO claimed
EP-1660507-B9 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON INC (US) 2010-03-24 EP claimed
EP-1660507-B1 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON INC (US) 2009-08-05 EP claimed
EP-1670804-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC Biotech AG (DE) 2006-06-21 EP claimed
WO-2005023818-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC BIOTECH AG (DE) 2005-03-17 WO claimed
EP-0975421-A2 PREPARATION OF LOW-DUST STABILISERS Ciba SC Holding AG (CH) 2000-02-02 EP claimed
WO-1998046342-A2 PREPARATION OF LOW-DUST STABILISERS CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) 1998-10-22 WO claimed
EP-0415631-B1 Electrodeposition of palladium films AMERICAN TELEPHONE & TELEGRAPH (US) 1994-05-18 EP claimed
EP-0415631-A1 Electrodeposition of palladium films AT&T Corp. (US) 1991-03-06 EP claimed
US-4911799-A Electrodeposition of palladium films AT&T BELL LABORATORIES (US) 1990-03-27 US claimed
CN-117466897-A Highly selective FGFR2 inhibitors 深圳福沃药业有限公司 2024-01-30 CN disclosed
WO-2023202625-A1 FGFR2 INHIBITOR AND METHOD FOR USING SAME 深圳福沃药业有限公司 2023-10-26 WO disclosed
CN-116903628-A FGFR2 inhibitors and methods of use 深圳福沃药业有限公司 2023-10-20 CN disclosed
US-10233152-B2 LSD1 inhibitors Mirati Therapeutics, Inc. (US) 2019-03-19 US disclosed
US-4911799-A Electrodeposition of palladium films AT&T BELL LABORATORIES (US) 1990-03-27 US disclosed
US-4911799-A Electrodeposition of palladium films AT&T BELL LABORATORIES (US) 1990-03-27 US disclosed
US-4515596-A Process for aftertreating dyed fibrous material made of or containing cellulose CIBA-GEIGY CORPORATION (US) 1985-05-07 US disclosed
US-4017256-A FIBER DYEABLE WITH DISPERSE DYES AND FIBER DYEABLE WITH REACTIVE DYES CIBA-GEIGY CORPORATION (US) 1977-04-12 US disclosed
US-3951588-A Process for dyeing and printing or optical brightening of cellulose materials CIBA-GEIGY CORPORATION (US) 1976-04-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10233152-B2 LSD1 inhibitors KDM1B, KDM1A, KDM3A HSD11B1 1315/4885L3MBTL1 1119/4885CA12 4254/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.